Loyale

Loyal is a clinical-stage veterinary biotech developing the world’s first drugs intended to extend the healthy lifespan of dogs. The company has achieved several industry milestones including what it believes to be the FDA’s first-ever formal acceptance that a drug can be developed and approved specifically for lifespan extension. Its lead program LOY‑002 has entered pivotal trials (“STAY study”) with over 1,000 senior dogs enrolled across more than 50 U.S. veterinary sites. Three products are currently in development targeting both large-breed and senior dogs. Pending regulatory approval, commercial launch could occur as soon as early 2025[2][4][7].